---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-293874"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:31:36.377309+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Shattuck reports 79% ORR in frontline HR-MDS and 27% CR/CRi in TP53m AML from SL-172154 trial

## Summary
- 79% objective response rate (ORR) with 64% complete response (CR)/marrow CR in 14 evaluable frontline HR-MDS patients.
- 27% initial CR/CRi in 11 evaluable frontline TP53m AML patients; 5 achieved stable disease with decreasing blasts.
- SL-172154 + azacitidine showed acceptable safety; no destructive anemia; most common TEAE was infusion-related reaction.
- Cohorts expanding; Shattuck expects next data update by mid-2024.
- Monotherapy response in R/R AML patient allowed stem cell transplant; patient remains disease-free.

## SEC filing metadata
- accession: 0001193125-23-293874
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312523293874/0001193125-23-293874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312523293874/d664766d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-293874
- JSON: https://secwatch.observer/filing/0001193125-23-293874.json
- Plain text: https://secwatch.observer/filing/0001193125-23-293874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.